What Is CJC-1295?

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that stimulates natural GH production from the pituitary gland. By working through the body's own hormonal pathways, it raises GH and IGF-1 levels while preserving the natural feedback mechanisms that prevent hormone excess.

The peptide is available with DAC (Drug Affinity Complex) for sustained release or without DAC (Mod GRF 1-29) for shorter-duration pulses. Both forms effectively elevate GH and IGF-1, which are directly relevant to tendon biology and repair.

Understanding Tendon Biology and Injury

Tendons are dense connective tissues that connect muscle to bone. They are composed primarily of type I collagen fibers arranged in parallel bundles, giving them the tensile strength needed to transmit muscular force. The cells within tendons (tenocytes) are responsible for producing and maintaining this collagen matrix.

Tendon injuries are notoriously slow to heal for several reasons:

• Low blood supply: Compared to muscle, tendons receive limited blood flow, which restricts the delivery of nutrients and healing factors.
• Low cellular density: Tendons contain fewer cells per unit volume than most tissues, meaning there are fewer repair workers available.
• Mechanical demands: Tendons are under near-constant mechanical stress, which can disrupt the healing process.
• Age-related decline: Collagen turnover in tendons slows with age, partly due to declining GH and IGF-1 levels.

This is precisely why growth hormone's effects on collagen synthesis and cellular activity are relevant. Tendon repair depends on the same biological processes that GH supports.

How Growth Hormone Supports Tendon Repair

Collagen Synthesis

Type I collagen is the structural backbone of tendons. GH and IGF-1 directly stimulate fibroblasts and tenocytes to produce more collagen. A landmark study published in the Journal of Physiology demonstrated that GH administration significantly increased collagen synthesis rates in human tendon and skeletal muscle.

This is not a minor effect. The study showed that systemic GH supplementation produced measurable increases in tendon collagen synthesis, suggesting that GH optimization could meaningfully support the repair process.

IGF-1 and Tenocyte Activity

IGF-1 is the primary mediator of GH's effects on connective tissue. IGF-1 receptors are expressed on tenocytes, and IGF-1 signaling promotes tenocyte proliferation, migration to injury sites, and collagen production. In animal models of tendon injury, IGF-1 administration has improved healing outcomes, including better collagen organization and increased tensile strength of repaired tendons.

Extracellular Matrix Remodeling

Tendon repair is not just about producing new collagen. The newly deposited collagen must be properly organized and cross-linked to restore mechanical strength. GH and IGF-1 support the matrix metalloproteinases (MMPs) and other enzymes involved in tissue remodeling, helping to create properly organized, functional tendon tissue rather than disorganized scar tissue.

Blood Supply Support

GH promotes angiogenesis and vascular health. For tendons, which already have limited blood supply, any improvement in local circulation can accelerate healing by delivering more nutrients, growth factors, and immune cells to the injury site.

Dosing and Administration

Standard CJC-1295 dosing for GH optimization, which may support tendon repair:

• CJC-1295 with DAC: 1 to 2 mg subcutaneously once or twice per week.
• CJC-1295 without DAC (Mod GRF 1-29): 100 to 300 mcg subcutaneously 1 to 3 times daily.
• Combined with ipamorelin: Frequently used together for synergistic GH release.

For tendon recovery, consistency is key. Tendon healing is a slow process (weeks to months), and sustained GH optimization over this period is more important than any single injection. Evening dosing supports overnight repair processes.

Nutritional support is also critical. Ensure adequate protein intake (particularly collagen-supporting amino acids like glycine, proline, and hydroxyproline) and vitamin C, which is essential for collagen cross-linking. For complete dosing information, see our CJC-1295 dosage guide.

Benefits and Expected Results

Tendon healing is inherently slow, and CJC-1295 should be viewed as a support tool within a comprehensive recovery plan:

• Week 1 to 4: GH and IGF-1 levels begin to optimize. The biological environment for tendon repair improves, though visible changes are unlikely this early.
• Month 1 to 2: Enhanced collagen synthesis may begin to accelerate the early phases of tendon repair. Patients sometimes report reduced pain or stiffness at the injury site.
• Month 2 to 4: More noticeable healing progress. Improved exercise tolerance and reduced discomfort during physical therapy or rehabilitation exercises.
• Month 4 to 6: Tendon remodeling phase. GH-supported collagen organization may lead to stronger repair tissue. Functional improvements become more apparent.
• Month 6 and beyond: Continued remodeling. Tendon healing can take 6 to 12 months for full maturation. Sustained GH optimization supports this entire process.

CJC-1295 should complement, not replace, standard tendon rehabilitation: rest, physical therapy, progressive loading, and any treatments recommended by your orthopedic provider.

Side Effects and Safety

CJC-1295 is well-tolerated at standard doses. Common side effects include:

• Injection site reactions
• Mild headache
• Facial flushing
• Temporary water retention
• Tingling in extremities

A specific consideration for tendon injuries: while GH supports healing, returning to activity too quickly because you "feel better" can risk re-injury. GH optimization may reduce pain and improve function before the tendon has fully healed. Follow your rehabilitation timeline and provider's guidance rather than symptoms alone.

Contraindications include active cancer, pregnancy, breastfeeding, and hypersensitivity. See our CJC-1295 side effects guide for complete safety information.

Who Is a Good Candidate?

CJC-1295 for tendon repair may be beneficial for:

• Adults recovering from tendon injuries (tendinitis, tendinosis, partial tears)
• Patients with chronic tendon problems that have been slow to respond to conventional treatment
• Athletes or active individuals who want to optimize their tendon recovery environment
• Older adults whose age-related GH decline may be contributing to slower connective tissue repair
• Those preparing for or recovering from tendon surgery

Complete tendon ruptures require surgical evaluation and repair. CJC-1295 may support post-surgical healing but does not replace the need for surgery in cases of complete tears.

Frequently Asked Questions

How does CJC-1295 compare to BPC-157 for tendons?

BPC-157 has more direct, localized evidence for tendon healing in animal studies. CJC-1295 works systemically through GH and IGF-1 to support collagen synthesis and tissue repair. Many practitioners use both: BPC-157 for local tissue effects and CJC-1295 for systemic GH optimization. See our BPC-157 benefits guide for BPC-157 details.

Can CJC-1295 help with tendinitis?

Tendinitis (acute tendon inflammation) and tendinosis (chronic tendon degeneration) may both benefit from GH optimization. For tendinosis in particular, where the underlying problem is collagen degeneration, CJC-1295's collagen-stimulating effects are especially relevant. However, proper rehabilitation and activity modification remain the cornerstones of treatment.

How long should I use CJC-1295 for tendon recovery?

Given the slow nature of tendon healing (typically 3 to 12 months depending on severity), sustained CJC-1295 use throughout the recovery period may provide the most benefit. Your physician can help determine the appropriate duration based on your specific injury and healing progress.

Can CJC-1295 prevent tendon injuries?

By supporting collagen synthesis and tendon health on an ongoing basis, GH optimization may help maintain stronger, more resilient tendons. This could theoretically reduce injury risk, though no study has directly tested CJC-1295 for tendon injury prevention.